Top-Line Results of the Phase 3 ZIRCON Study

EP: 1.The Evolvement of Imaging in ccRCC

EP: 2.The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses

EP: 3.Strengths and Weaknesses of Imaging Modalities in ccRCC

EP: 4.Treatment or Lack of Treatment of Small Renal Masses

EP: 5.Decision-Making in Small Renal Masses

EP: 6.Current Unmet Needs in ccRCC Diagnosis

EP: 7.Early Detection of ccRCC

EP: 8.Key Benefits of PET in ccRCC Risk Stratification

EP: 9.The ZIRCON Trial

EP: 10.The MOA of TLX250

Now Viewing

EP: 11.Top-Line Results of the Phase 3 ZIRCON Study

EP: 12.Risk Stratification in ccRCC: The Impact in Patient Populations

EP: 13.Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging

EP: 14.Overcoming Challenges for Wider Adoption of TLX250

EP: 15.The Future of PET Imaging Agents

EP: 16.The Logistical Challenges in ccRCC Treatment

Diagnostic Performance of the ZIRCON Trial

Main Discussion Topics:

• A 93% to 95% positive predictive value for clear cell renal cell carcinoma (ccRCC)
• A 75% negative predictive value
• Important observation that non–clear cell positive cases were still malignant
• A positive test indicates cancer with high probability.

Key Points for Physicians:

• When the test is positive, there is a greater than 90% probability of ccRCC.
• The 7% of positive tests that weren’t ccRCC were still malignant tumors.
• A positive test strongly supports proceeding with intervention.
• A simplified interpretation: If it lights up, it’s very likely cancer.

Notable Insights:

A key clinical value is that a positive test is highly reliable for indicating malignancy, even in the small percentage that aren’t specifically ccRCC.

Clinical Significance:

The high positive predictive value provides actionable information that can guide clinical decision-making toward appropriate intervention.